Endotoxin removal from whole blood by a novel adsorption resin: Efficiency and hemocompatibility

International Journal of Artificial Organs

Volumn 27, Issue 6, 2004, Pages 480-487

  Amoureux, Marie Claude ^a   Rajapakse, N ^a   Hegyi, E ^a   Le, D ^b   Grandics, P ^a   Szathmary, S ^a  

^a Clarigen Inc   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Adsorption; Endotoxin; Extracorporeal; Hemocompatibility; Sepsis; Whole blood

Indexed keywords

BACTERIA; BLOOD; RESINS;

ADSORPTION RESINS; DOWN-STREAM; ENDOTOXIN; ENDOTOXIN REMOVAL; EXTRACORPOREAL; HAEMOCOMPATIBILITY; IN-VIVO; SEPSIS; STRUCTURAL COMPONENT; WHOLE BLOOD;

COAGULATION;

BLOOD CLOTTING FACTOR; COMPLEMENT; ENDOTOXIN; RESIN; ANTIINFECTIVE AGENT; COMPLEMENT COMPONENT C3A; FIBRINOGEN; LEUKOCYTE ELASTASE; LIGAND; OFLOXACIN; SEPHAROSE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; BLOOD COMPATIBILITY; CELL LOSS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENDOTOXEMIA; HEMADSORPTION; HEMODIALYSIS; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; NONHUMAN; SEPSIS; STENOTROPHOMONAS MALTOPHILIA; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; ADSORPTION; AFFINITY CHROMATOGRAPHY; BLOOD; CELL COUNT; GRAM NEGATIVE INFECTION; HEMOSTASIS; METABOLISM; METHODOLOGY; MONOCYTE; SEPTIC SHOCK;

ADSORPTION; ANTI-INFECTIVE AGENTS; BLOOD COAGULATION FACTORS; CELL COUNT; CHROMATOGRAPHY, AFFINITY; COMPLEMENT C3A; ENDOTOXINS; FIBRINOGEN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOSTASIS; HUMANS; LEUKOCYTE ELASTASE; LIGANDS; MONOCYTES; OFLOXACIN; SEPHAROSE; SHOCK, SEPTIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4644293125     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880402700606     Document Type: Article

References (32)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29: 1303-10.
2. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34: 1084-93.
3. Stegmayr BG. Is there a future for adsorption techniques in sepsis? Blood Purif 2000; 18: 149-55.
4. Berlot G, Lucangelo U, Galimberti G, Sganga G. Plasma-pheresis in sepsis. Contrib Nephrol 2001; 132: 391-9.
5. Stegmayr BG. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther Apher 2001; 5: 123-7.
6. Tetta C, Gianotti L, Cavaillon JM, et al. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000; 28: 1526-33.
7. Tetta C, Bellomo R, Brendolan A, et al. Use of adsorptive mechanisms in continuous renal replacement therapies in the critically ill. Kidney Int 1999; 72 (suppl): S15-9.
8. Bellomo R, Ronco C. Continuous renal replacement therapy in the intensive care unit. Intensive Care Med 1999; 25: 781-9.
9. Zimmermann M, Busch K, Kuhn S, Zeppezauer M. Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med 1999; 37: 373-9.
10. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin). Therap Apher Dial 2003; 7: 108-14.
11. Staubach KH, Boehme M, Zimmermann M, Otto V. A new endotoxin adsorption device in Gram-negative sepsis: Use of immobilized albumin with the MATISSE adsorber. Transfus Apheresis Sci 2003; 29: 93-8.
12. Amoureux MC, Hegyi E, Le D, et al. A new method for removing endotoxin from plasma using a hemocompatible affinity chromatography technology, applicable for extracorporeal treatment of septic patients. J Endotoxin Res 2004; 10: 85-95.
13. Siami GA, Siami FS. Membrane plasmapheresis in the United States: A review over the last 20 years. Ther Apher 2001; 5: 315-20.
14. Strand SE, Sjogren HO, Chen J, et al. In: Abrams PG, Fritzberg AR, eds. Extracorporeal techniques in radioimmunotherapy. NY: Marcel & Dekker, 2000: pp. 223-43.
15. Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 107: 280-8.
16. Mezzano D, Habash J, Aranda E, et al. Platelet consumption and platelet dysfunction during and after surgery with extracorporeal circulation. Sangre 1986, 31: 425-34.
17. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991; 75: 388-93.
18. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
19. Bosch T, Schmidt B, Spencer PC, et al. Ex vivo biocompatibility evaluation of a new modified cellulose membrane. Artif Organs 1987; 11: 144-8.
20. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion, a new procedure for LDL apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 1997; 21: 1060-5.
21. Bosch T, Lennertz A, Duhr C, Fink E, Samtleben W. Ex vivo biocompatibility of avidin-agarose: A new device for direct adsorption of biotinylated antibodies from human whole blood. Artif Organs 2000; 24: 696-704.
22. Park KD, Suzuki K, Lee WK, et al. Platelet adhesion and activation on polyethylene glycol modified polyurethane surfaces. Measurement of cytoplasmic calcium. ASAIO J 1996; 42: M876-81.
23. Zhang M, Desai T, Ferrari M. Proteins and cells on PEG immobilized silicon surfaces. Biomaterials 1998; 19: 953-60.
24. Vladkova T, Krasteva N, Kostadinova A, Altankov G. Preparation of PEG-coated surfaces and a study for their interaction with living cells. J Biomater Sci Polym Ed 1999; 10: 609-20.
25. Deible CR, Petrosko P, Johnson PC, Beckman EJ, Russell AJ, Wagner WR. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Biomaterials 1999, 20: 101-9.
26. Alcantar NA, Aydil ES, Israelachvili JN. Polyethylene glycolcoated biocompatible surfaces. J Biomed Mater Res 2000; 51: 343-51.
27. Sirolli V, Di Stante S, Stuard S, et al. Biocompatiblity and functional performance of a polyethylene glycol acid-grafted cellulosic membrane for hemodialysis. Int J Artif Organs 2000; 23: 356-64.
28. Uchida, Yamato M, Ito E, et al. Two different types of nonthrombogenic surfaces: PEG suppresses platelet adhesion ATP-independently but HEMA-St block copolymer requires ATP consumption of platelets to prevent adhesion. J Biomed Mater Res 2000; 50: 585-90.
29. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-82.
30. Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180: 1584-9.
31. Kodama M. Hemoperfusion using a polymyxin B immobilized fiber column for the removal of endotoxin. In: Levin J, Alving CR, Munford RS, Stutz PL, eds. Bacterial endotoxin: Recognition and effector mechanisms 1993; pp. 389-98.
32. Shalaby MR, Waage A, Aarden L, Espevik T. An overview of the history and biologic properties of tumor necrosis factors. Spring Semin Immunopathol 1986; 9: 33-7.